相关实验视频

Updated: Jul 17, 2025

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
07:17

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

531

对于复发性质瘤而言,埃托波的价值

Matthijs van der Meulen1,2, Manik Chahal1,3, Warren P Mason1

  • 1Departments of Neurology and Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
|August 29, 2023
PubMed
概括

埃托胺单疗为具有有限选择的多重复发性质瘤患者提供了耐受性良好的选择. 这种化疗导致严重预治疗的成年人平均整体生存时间为4个月.

关键词:
质瘤是一种质瘤.化疗 化疗是一种化学疗法.这里是etoposide的位置.经常性的反复的反复.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K